Brief: Immuneering Submits IND Application For Phase 1/2A Trial Of IMM-1-104
U.S. RESEARCH ROUNDUP-Isoplexis, Seer, Wesco International
Brief: Immuneering Corp Files For Mixed Shelf Of Up To $200 Million
Brief: Immuneering Reports Second Quarter 2022 Financial Results And Recent Business Highlights
Brief: Immuneering Reports Data In Two Preclinical Abstracts At The ASCO 2022
Brief: Immuneering Reports First Quarter 2022 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP- Blend Labs, Unifirst, Vertiv Holdings
U.S. RESEARCH ROUNDUP- Beauty Health, Mister Car Wash, Nuvei
Brief: Immuneering Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Business Updates
Brief: PepGen Says Laurie Keating Appointed As Chair Of Co's Board
Brief: Immuneering Strengthens Board Of Directors With The Appointment Of Diana F. Hausman, M.D.
Brief: Immuneering Reports Compelling Preclinical Data On IMM-1-104 In NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event
Brief: Immuneering Says On Dec 22 Entered Into A Share Purchase Agreement With Bioarkive, Inc
Brief: Immuneering Added To The Nasdaq Biotechnology Index
NASDAQ RESUMED AT 09:45 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:39 AM
Brief: Immuneering Reports Third Quarter 2021 Financial Results
Brief: Immuneering Reports Compelling Preclinical Data On Imm-1-104 At Aacr-Nci-Eortc
Brief: Immuneering To Present Preclinical Data At AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics